




INFORMAȚII PERSONALE

Cojocaru Monica Lucia



POZITIE ACTUALA

Medic primar gastroenterolog, Asistent universitar, Doctor in Stiinte Medicale

LOCUL DE MUNCA

Institutul Clinic de Boli Digestive si Transplant Hepatic Fundeni

- Medic rezident gastroenterologie 2012-2015 (Institutul Clinic de Boli Digestive si Transplant Hepatic Fundeni)
- Medic specialist gastroenterologie 2016- 2020 (Institutul Clinic de Boli Digestive si Transplant Hepatic Fundeni)
- Asistent universitar gastroenterologie octombrie 2016- octombrie 2021 (Institutul Clinic de Boli Digestive si Transplant Hepatic Fundeni)

EDUCAȚIE & FORMARE

- 2002 – 2005 Eleva- Liceul Radu Greceanu, Slatina
- 2005 – 2011 Student – Universitatea de Medicina si Farmacie Carol Davila, Bucuresti
- 2012-2015 Medic rezident gastroenterologie 2015 (Institutul Clinic de Boli Digestive si Transplant Hepatic Fundeni)
- 2016- 2020 Medic specialist gastroenterologie 2015 (Institutul Clinic de Boli Digestive si Transplant Hepatic Fundeni)
- 2016-2023 Student Doctorand – Scoala Doctorala – Universitatea de Medicina si Farmacie Carol Davila , Bucuresti
- 2020- prezent Medic primar gastroenterologie (Institutul Clinic de Boli Digestive si Transplant Hepatic Fundeni)
- Doctor in stiinte medicale – nr 6275 , 21 noiembrie 2023, serie J 0059479

Endoscopie digestiva diagnostica si terapeutica

COMPETENTE PROFESIONALE

Limba maternă

Romana

Alte limbi străine cunoscute

INTELEGERE		VORBIRE		SCRIERE
Ascultare	Citire	Participare la conversație	Discurs oral	
B2	B2	B2	B2	B2

ENGLEZA:

Competențe de comunicare

Bune abilitati de public speaking, dobandite in urma interactiunii cu grupele de studenti la stagii si cursuri; am coordonat multiple lucrari de licenta, oferind feedback si suport dedicat.

Competențe dobândite la locul de muncă

- Buna abilitatate de comunicare si relationare cu oamenii. Rezolvarea farmacologica si hemostaza endoscopica a hemoragiilor digestive superioare/ inferioare. Abordarea si managementul pacientilor cu boli inflamatorii intestinale sau hepato-bilio- pancreatice.
- Curs de endoscopie digestiva terapeutica , seria A Nr. 0077304, din 3.04.2020

PREGATIRE POST-UNIVERSITARA

- United European Gastroenterology Week, noiembrie 2013
- Al XXXIV-lea Congres National de Gastroenterologie, Hepatologie si Endoscopie Digestiva, Oradea, iulie 2014
- Scoala Nationala de Vara de Gastroenterologie si Hepatologie, Paltinis, iulie 2014
- The 9th Congress of ECCO ,Copenhaga, februarie 2014
- The 10th Congress of ECCO, Barcelona, februarie 2015
- Al XXXV-lea Congres National de Gastroenterologie, Hepatologie si Endoscopie Digestiva, Iasi, iunie 2015
- Al 7 lea Simpozion Anual de Boli Inflamatorii Intestinale, RCCC, septembrie 2015
- 11th Congress of ECCO – Inflammatory Bowel Diseases, Amsterdam, martie 2016
- Al XXXVI-lea Congres National de Gastroenterologie, Hepatologie si Endoscopie Digestiva, Cluj-Napoca, iunie 2016
- Scoala Nationala de Vara de Gastroenterologie si Hepatologie, Ramnicu Valcea, iulie 2016
- IBD COP Merck , Belgia, septembrie 2016
- Al VIII - lea Simpozion National IBD al RCCC, Bucuresti, octombrie 2016
- 19th Dusseldorf International Endoscopy Symposium, , Dusseldorf , februarie 2017
- 12th Congress of ECCO, Barcelon, februarie 2017 2nd D-ECCO Workshop2nd D-ECCO Workshop, februarie 2017
- 6th S-ECCO IBD Masterclass, februarie 2017
- Al XXXVII-lea Congres National de Gastroenterologie, Hepatologie si Endoscopie Digestiva,

Bucuresti,
iunie 2017

- Scoala Nationala de Vara de Gastroenterologie si Hepatologie, Covasna, iulie 2017
- 53rd ECCO Educational Workshop, Bucuresti, octombrie 2017
- UC & CD Clinical Experience Exchange Programme , Belgia, decembrie 2017
- 20th Dusseldorf International Endoscopy Symposium, Dusseldorf, februarie 2018
- 13th ECCO Congress, Viena , februarie 2018
- Scoala Nationala de Vara de Gastroenterologie si Hepatologie, Paltinis, iulie 2018
- 21th Dusseldorf International Endoscopy Symposium, , Dusseldorf, februarie 2019
- IBD Peer Preceptorship, Amsterdam, octombrie 2019
- The 14th Congress of ECCO , Copenhaga, martie 2019
- 8th S-ECCO Masterclass martie 2019
- 13th N-ECCO Network Meeting , martie 2019
- 4th H-ECCO IBD Masterclas, martie 2019
- The 16th Congress of ECCO, July 2021, Virtual
- Digestive Endoscopy Cluj 2021, Cluj-Napoca, septembrie 2021
- Al 41-lea Congres National de Gastroenterologie, Hepatologie si Endoscopie Digestiva, Bucuresti, iulie 2022
- Bucharest PancreaticFest 2022- Al 9-lea Curs de Patologie Pancreatica si al 10-lea Workshop de Ecoendoscopie in Patologia Pancreatica, Bucuresti, septembrie 2022
- 30th United European Gastroenterology Week, Viena, octombrie 2022
- 25th Dusseldorf International Endoscopy Symposium , Dusseldorf, februarie 2023
- Al 42-lea Congres National de Gastroenterologie, Hepatologie si Endoscopie Digestiva, Bucuresti, Iasi, iunie 2022

EXPERIENTA IN CERCETARE STIINTIFICA:

1. Bergamot: "A Phase III, Randomized, Double-blind, Placebo controlled, multicenter study to evaluate the efficacy and safety of Etrolizumab as an induction and maintenance treatment for patients with moderately to severely active Crohn's disease" (2018-2020)
2. Gardenia: "Phase III, Randomized, Multicenter, double blind, double dummy study to evaluate the efficacy and safety of Etrolizumab compared with Infliximab in patients with moderate to severe active ulcerative colitis who are naïve to TNF inhibitors" (2018-2020)
3. A phase 3 randomized, double blind, placebo controlled parallel group efficacy and safety study of SHP647 as maintenance therapy in subjects with moderate to severe ulcerative colitis (SHP UC 303) (2019-2021)
4. A phase 3 long term safety extension study of SHP 647 in subjects with moderate to severe ulcerative colitis or Crohn's disease (AIDA) (2019-2021)
5. A phase 3 randomized, double blind, placebo controlled parallel group efficacy and safety study of SHP647 as induction therapy in subjects with moderate to severe Crohn's disease (CARMEN CD305) (2019-2021)

6. A phase 3, randomized, double blinded, placebo controlled parallel group, efficacy and safety study of SHP647 as maintenance therapy in subjects with moderate to severe Crohn's disease (CARMEN CD307) (2019-2021)
7. A phase 3 multicenter, randomized, double blind, parallel, placebo controlled induction study of Mirikizumab in conventional failed and biologic failed patients with moderately to severely active ulcerative colitis (2020-2022)
8. A phase 3, multicenter, randomized, double blind, placebo controlled study of oral Ozanimod as induction therapy for moderately to severely active Crohn's disease (RPC01-3201) (2019-2022)
9. A phase 3, multicenter, randomized, double blind, placebo controlled study of oral Ozanimod as maintenance therapy for moderately to severely active Crohn's disease (RPC01-3203) (2019-2022)
10. A phase 3, multicenter, open label extension study of oral Ozanimod for moderately to severely active Crohn's disease (RPC01-3204) (2019-2022)
11. A phase 2, multicenter, randomized, double-blind, placebo-controlled, dose-finding study to evaluate the efficacy and safety of IMU-838 for induction and maintenance therapy in moderate-to-severe ulcerative colitis (CALDOSE-1) (2020-2021)